17-Mar-2008 - The costs of introducing any formal good manufacturing practice (GMP) requirements for potentially high-risk pharmaceutical excipients in the European Union would far exceed the likely benefits, concludes an impact assessment for the European Commission.
Link to Article
in-pharmatechnologist.com
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
GMP an unnecessary burden for excipients, review concludes
by
Alex Hsieh on behalf of Professor Henry Wang
on Mon 17 Mar 2008 11:44 PM EDT | Permanent Link
| Cosmos
No comments found.
|
Search
Links
|
||